Step 7: REMOVE the perforated oval (see Figure H).
Nota: When removing the oval, it is possible that the white support sheet remains.
This is correct.
Figure I: Frontal face of the blister
Step 8: TURN THE BLISTER OVER to see the frontal face.
PUSH the capsule to remove it (see Figure I).
Figure J: Frontal face of the blister
Step 9: The next day, move to the white circle from the top row marked as Day 2.
Press the white circle to perforate it (see Figure J).
Nota: Perforating this white circle will help you remember which days not to take the medication.
Take 1 Galafold capsule every two days.
Close and store the box after each use.
After Day 2, move to Day 3 of the blister.
Alternate the days you take the capsule and perforate the white circles, until Day 28, inclusive.
Figure K: Frontal face of the unfolded blister
If you take more Galafold than you should
If you take more capsules than you should, stop taking the medication and consult your doctor. You may experience headaches and dizziness.
If you forget to take Galafold
If you forget to take the capsule at the usual time and remember later, you can take the capsule only if it is within the 12-hour interval following the usual time to take the dose. If more than 12 hours have passed, you should resume Galafold on the corresponding day and at the usual time, according to the dosing schedule of alternate days. Do not take a double dose to compensate for the missed doses.
If you interrupt treatment with Galafold
You should not interrupt treatment without first speaking with your doctor.
If you have any other doubts about the use of this medication, ask your doctor, pharmacist, or nurse.
Like all medications, this medication may produce adverse effects, although not all people may experience them.
Very Common: may affect more than 1 in 10 people
Common: may affect up to 1 in 10 people
|
|
|
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through thenational notification system included in theAppendix V. By reporting adverse effects, you can contribute to providing more information about the safetyof this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box and the blister pack after CAD. The expiration date is the last day of the month indicated.
This medication does not require any special storage temperature. Store in the original packaging to protect it from moisture.
Medicines should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the containers and medications that you no longer need. This will help protect the environment.
Galafold Composition
Capsule content: pregelatinized maize starch and magnesium stearate
Capsule coating: gelatin, titanium dioxide (E171) and indigo carmine (E132)
Printing ink: shellac, iron oxide black and potassium hydroxide
Appearance of Galafold and packaging contents
Hard blue and white opaque capsules marked with "A1001" in black ink, hard capsule size 2 (6.4 x 18.0 mm) containing a white to light brown powder.
Galafold is available in a blister pack of 14 capsules.
Marketing Authorization Holder
Amicus Therapeutics Europe Limited
Block 1, Blanchardstown Corporate Park
Ballycoolin Road
Blanchardstown, Dublin
D15 AKK1
Ireland
Tel: +353 (0) 1 588 0836
Fax: +353 (0) 1 588 6851
e-mail:[email protected]
Manufacturer
Almac Pharma Services (Ireland) Limited
Finnabair Industrial Estate
Dundalk, Co. Louth
A91 P9KD
Ireland
You can request more information about this medicine by contacting the local representative of the marketing authorization holder (if you cannot contact your Amicus representative by phone, please contact us via the following email address):
Belgium Amicus Therapeutics Europe Limited Tel: (+32) 0800 89172 e-mail: [email protected] | Lithuania Amicus Therapeutics Europe Limited Tel.: (+370) 8800 33167 e-mail: [email protected] |
Bulgaria Amicus Therapeutics Europe Limited Phone: (+359) 00800 111 3214 Email:[email protected] | Luxembourg Amicus Therapeutics Europe Limited Tel/Tel: (+352) 800 27003 e-mail: [email protected] |
Czech Republic Amicus Therapeutics Europe Limited Tel.: (+420) 800 142 207 e-mail:[email protected] | Hungary Amicus Therapeutics Europe Limited Tel.: (+36) 06 800 21202 e-mail: [email protected]om |
Denmark Amicus Therapeutics Europe Limited Tlf.: (+45) 80 253 262 e-mail: [email protected] | Malta Amicus Therapeutics Europe Limited Tel: (+356) 800 62674 e-mail: [email protected] |
Germany Amicus Therapeutics GmbH Tel.: (+ 49) 0800 000 2038 E-Mail: [email protected] | Netherlands Amicus Therapeutics BV Tel: (+ 31) 0800 022 8399 e-mail: [email protected] |
Estonia Amicus Therapeutics Europe Limited Tel: (+372) 800 0111 911 e-post: [email protected] | Norway Amicus Therapeutics Europe Limited Tlf: (+47) 800 13837 e-post: [email protected] |
Greece Amicus Therapeutics Europe Limited Phone: (+30) 00800 126 169 e-mail:[email protected] | Austria Amicus Therapeutics Europe Limited Tel: (+43) 0800 909 639 E-Mail: [email protected] |
Spain Amicus Therapeutics S.L.U. Tel: (+34) 900 941 616 e-mail: [email protected] | Poland Amicus Therapeutics Europe Limited Tel.: (+48) 0080 012 15475 e-mail: [email protected] |
France Amicus Therapeutics SAS Tél: (+33) 0 800 906 788 e-mail: [email protected] | Portugal Amicus Therapeutics Europe Limited Tel: (+351) 800 812 531 e-mail: [email protected] |
Croatia Amicus Therapeutics Europe Limited Tel: (+385) 0800 222 452 e-pošta: [email protected] | Romania Amicus Therapeutics Europe Limited Tel.: (+40) 0808 034 288 e-mail: [email protected] |
Ireland Amicus Therapeutics Europe Limited Tel: (+354) 1800 936 230 e-mail: [email protected] | Slovenia Amicus Therapeutics Europe Limited Tel.: (+386) 0800 81794 e-pošta: [email protected] |
Iceland Amicus Therapeutics Europe Limited Phone: (+354) 800 7634 Email: [email protected] | Slovakia Amicus Therapeutics Europe Limited Tel.: (+421) 0800 002 437 e-mail: [email protected] |
Italy Amicus Therapeutics S.r.l. Tel: (+39) 800795 572 e-mail: [email protected] | Finland Amicus Therapeutics Europe Limited Tel: (+358) 0800 917 780 e-mail: [email protected] |
Cyprus Amicus Therapeutics Europe Limited Phone: (+357)800 97595 e-mail:[email protected] | Sweden Amicus Therapeutics Europe Limited Tfn: (+46) 020 795 493 e-post: [email protected] |
Lithuania Amicus Therapeutics Europe Limited Tel.: (+371) 800 05391 e-pasts: [email protected] | United Kingdom (Northern Ireland) Amicus Therapeutics, UK Limited Tel: (+44) 08 0823 46864 e-mail: [email protected] |
Last update of this leaflet
For detailed information about this medicine, please visit the website of the European Medicines Agency:http://www.ema.europa.eu. There are also links to other websites about rare diseases and orphan medicines.
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.